LXRX Q3 2024 Earnings — Lexicon Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

LXRXLexicon Pharmaceuticals, Inc.

$704M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+980.2% YoY

Gross Profit

$2M95.9% margin

Operating Income

-$64M-3639.6% margin

Net Income

-$65M-3703.5% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

+6.3%

Cash Flow

Operating Cash Flow

-$54M

Free Cash Flow

-$54M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$321M

Total Liabilities

$143M

Stockholders' Equity

$179M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$162,000	+980.2%
Gross Profit	$2M	$155,000	+983.2%
Operating Income	-$64M	-$50M	-28.3%
Net Income	-$65M	-$51M	-28.3%